Login to Your Account



FDA Plans To Take Closer Look At Postmarketing Requirements

By Kim Coghill


Tuesday, May 27, 2003
WASHINGTON - Companies required to conduct postmarketing studies should expect to find themselves under closer scrutiny by the FDA and the public as the government begins tracking progress on such trials in the Federal Register. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription